MX2018003077A - Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica. - Google Patents

Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.

Info

Publication number
MX2018003077A
MX2018003077A MX2018003077A MX2018003077A MX2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A
Authority
MX
Mexico
Prior art keywords
nash
alcoholic steatohepatitis
diagnosing
methods
mir
Prior art date
Application number
MX2018003077A
Other languages
English (en)
Inventor
Darteil Raphaél
Cordonnier Geneviéve
BROZEK John
Praca Emilie
BEN SUDRIK Fouad
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2018003077A publication Critical patent/MX2018003077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La invención se refiere a un método para el diagnóstico de esteatohepatitis no alcohólica (NASH), para determinar la actividad, la etapa, o la severidad de NASH o para clasificar un sujeto como un posible receptor o no receptor de un tratamiento de NASH. También se refiere a un kit para implementar el método de la invención, y los compuestos para usar en un método para el tratamiento de NASH, en donde el sujeto a tratarse se identifica, evalúa o clasifica de acuerdo al método de la invención.
MX2018003077A 2015-09-14 2016-09-14 Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica. MX2018003077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306412 2015-09-14
PCT/EP2016/071727 WO2017046181A1 (en) 2015-09-14 2016-09-14 Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2018003077A true MX2018003077A (es) 2018-05-28

Family

ID=54199140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003077A MX2018003077A (es) 2015-09-14 2016-09-14 Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.

Country Status (18)

Country Link
US (2) US11371098B2 (es)
EP (2) EP3712279B1 (es)
JP (2) JP6947721B2 (es)
KR (1) KR20180049098A (es)
CN (1) CN108138232B (es)
AU (1) AU2016323380B2 (es)
CA (1) CA2997336A1 (es)
DK (1) DK3350341T3 (es)
EA (1) EA201890724A1 (es)
ES (1) ES2891347T3 (es)
HK (1) HK1255351A1 (es)
HU (1) HUE056299T2 (es)
IL (1) IL257680B2 (es)
MX (1) MX2018003077A (es)
PH (1) PH12018500513A1 (es)
PT (1) PT3350341T (es)
WO (1) WO2017046181A1 (es)
ZA (1) ZA201801630B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252835A1 (en) 2012-01-27 2013-09-26 Lian Chye Winston Koh Methods for profiling and quantitating cell-free rna
AU2017242818B2 (en) * 2016-03-30 2023-04-27 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
CA3070038A1 (en) 2017-08-25 2019-02-28 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
BR112020004136A2 (pt) 2017-09-08 2020-09-08 Bristol-Myers Squibb Company fator de crescimento de fibroblastos modificado 21 (fgf-21) para uso nos métodos de tratamento de esteato-hepatite não alcoólica (nash)
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
KR20200051676A (ko) 2017-09-18 2020-05-13 장피트 비알콜성 지방 간 질환, 비알콜성 지방간염 및/또는 간 섬유화의 비침습성 진단
EP3546597A1 (en) 2018-03-28 2019-10-02 Sanofi Biomarker panel for nafld/nash
WO2020168118A1 (en) 2019-02-14 2020-08-20 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject
MX2021010475A (es) 2019-03-13 2021-10-01 Genfit Diagnostico de esteatohepatitis no alcoholica.
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
KR20210010100A (ko) 2019-07-19 2021-01-27 고려대학교 산학협력단 체질량지수와 자기공명영상을 이용한 비알코올성 지방간 질환 진단방법
CN110484605B (zh) * 2019-09-23 2020-07-28 中国人民解放军陆军军医大学第一附属医院 一种活细胞原位检测microRNA-34的基因及其制备方法和应用
CN110578003A (zh) * 2019-10-22 2019-12-17 安徽医科大学第二附属医院 miR-200a在制备肝癌诊断治疗试剂盒及在制备抗肿瘤药物中的应用
KR102341336B1 (ko) * 2019-11-20 2021-12-21 숙명여자대학교산학협력단 만성간질환의 예후 예측용 바이오마커 조성물
JP2023548156A (ja) * 2020-10-30 2023-11-15 ザ ジェネラル ホスピタル コーポレイション 肝疾患の評価のためのキット、試薬、及び方法
CN116507918A (zh) 2020-10-30 2023-07-28 基恩菲特公司 肝纤维化的诊断方法
WO2024038901A1 (ja) * 2022-08-17 2024-02-22 公益財団法人東京都医学総合研究所 肝疾患非侵襲性バイオマーカー及びこれを用いた肝疾患の検出

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058295A2 (en) * 2008-11-18 2010-05-27 Universite D'angers Non-invasive in vitro method for quantifying liver lesions
PL2641596T3 (pl) * 2009-11-26 2018-10-31 Genfit Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
DK2776590T3 (en) * 2011-11-07 2016-12-05 Roche Innovation Ct Copenhagen As Prognostic method of assessing the efficacy of MICRO-RNA-122 inhibitors for HCV + patients
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
WO2013125691A1 (ja) 2012-02-23 2013-08-29 住友ベークライト株式会社 テスト体液サンプルの分類方法
EP2684513A1 (en) * 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
WO2014049131A1 (en) * 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
KR20140147920A (ko) * 2013-06-19 2014-12-31 가톨릭대학교 산학협력단 비알코올성 지방간염 감별용 바이오마커 ｍｉＲ-34ａ
CN104293908A (zh) * 2014-06-18 2015-01-21 镇江市第三人民医院 用于检测非酒精性脂肪肝的血清miRNA标志物组合及应用

Also Published As

Publication number Publication date
HK1255351A1 (zh) 2019-08-16
AU2016323380B2 (en) 2023-01-05
US20220411874A1 (en) 2022-12-29
PT3350341T (pt) 2021-09-28
EP3350341A1 (en) 2018-07-25
IL257680B (en) 2022-11-01
AU2016323380A1 (en) 2018-03-29
PH12018500513A1 (en) 2018-09-24
IL257680B2 (en) 2023-03-01
CN108138232B (zh) 2023-07-18
CA2997336A1 (en) 2017-03-23
EP3712279B1 (en) 2024-03-20
ZA201801630B (en) 2019-01-30
JP2021144048A (ja) 2021-09-24
DK3350341T3 (da) 2021-09-27
ES2891347T3 (es) 2022-01-27
WO2017046181A1 (en) 2017-03-23
JP2018534542A (ja) 2018-11-22
EP3712279A1 (en) 2020-09-23
JP6947721B2 (ja) 2021-10-13
US20180265924A1 (en) 2018-09-20
KR20180049098A (ko) 2018-05-10
IL257680A (en) 2018-04-30
EA201890724A1 (ru) 2018-10-31
HUE056299T2 (hu) 2022-02-28
JP7274523B2 (ja) 2023-05-16
US11371098B2 (en) 2022-06-28
CN108138232A (zh) 2018-06-08
EP3350341B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
MX2019015159A (es) Composiciones, metodos y usos para asistir en el diagnostico, pronostico y tratamiento de la fibrosis pulmonar idiopatica.
MX2017008904A (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica.
WO2014160441A8 (en) Neuroactive steroids, compositions, and uses thereof
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
IN2013CN01129A (es)
EA201792012A1 (ru) Использование щелочных промывочных растворов во время хроматографии для удаления примесей
MX2016013261A (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
MX2021001709A (es) Composiciones y metodos para mejorar el enriquecimiento de genotecas.
MX2021002071A (es) Metodos relacionados con la gravedad y progresion de la lesion premaligna bronquial.
EP4047372A3 (en) Lipopolysaccharide-binding protein as biomarker for non-alcoholic fatty liver disease
MX359442B (es) Metodo para programar un episodio de diagnostico.
NZ738100A (en) Igfbp3 and uses thereof
IN2015KN00571A (es)
WO2019039817A3 (ko) 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
WO2015092046A3 (en) Prostate cancer biomarkers
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
GB2552271A (en) A method for diagnosing lung cancer
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2016012278A (es) Deteccion temprana de preeclampsia.
RS54437B1 (en) PROCEDURE FOR PREVENTION AND TREATMENT OF SEPS